247 related articles for article (PubMed ID: 25433527)
1. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.
Poelman CL; Hummers LK; Wigley FM; Anderson C; Boin F; Shah AA
J Rheumatol; 2015 Feb; 42(2):236-42. PubMed ID: 25433527
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis.
Takehara K; Ihn H; Sato S
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):151-6. PubMed ID: 23910617
[TBL] [Abstract][Full Text] [Related]
3. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
Le EN; Wigley FM; Shah AA; Boin F; Hummers LK
Ann Rheum Dis; 2011 Jun; 70(6):1104-7. PubMed ID: 21378404
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
Mendoza FA; Lee-Ching C; Jimenez SA
Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
[TBL] [Abstract][Full Text] [Related]
7. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.
Herrick AL; Lunt M; Whidby N; Ennis H; Silman A; McHugh N; Denton CP
J Rheumatol; 2010 Jan; 37(1):116-24. PubMed ID: 19955050
[TBL] [Abstract][Full Text] [Related]
8. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
Amjadi S; Maranian P; Furst DE; Clements PJ; Wong WK; Postlethwaite AE; Khanna PP; Khanna D;
Arthritis Rheum; 2009 Aug; 60(8):2490-8. PubMed ID: 19644851
[TBL] [Abstract][Full Text] [Related]
9. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
Mendoza FA; Nagle SJ; Lee JB; Jimenez SA
J Rheumatol; 2012 Jun; 39(6):1241-7. PubMed ID: 22467932
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
Postlethwaite AE; Wong WK; Clements P; Chatterjee S; Fessler BJ; Kang AH; Korn J; Mayes M; Merkel PA; Molitor JA; Moreland L; Rothfield N; Simms RW; Smith EA; Spiera R; Steen V; Warrington K; White B; Wigley F; Furst DE
Arthritis Rheum; 2008 Jun; 58(6):1810-22. PubMed ID: 18512816
[TBL] [Abstract][Full Text] [Related]
11. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
Chakravarty EF; Martyanov V; Fiorentino D; Wood TA; Haddon DJ; Jarrell JA; Utz PJ; Genovese MC; Whitfield ML; Chung L
Arthritis Res Ther; 2015 Jun; 17(1):159. PubMed ID: 26071192
[TBL] [Abstract][Full Text] [Related]
12. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.
Raja J; Nihtyanova SI; Murray CD; Denton CP; Ong VH
Rheumatology (Oxford); 2016 Jan; 55(1):115-9. PubMed ID: 26320139
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
Herrick AL; Pan X; Peytrignet S; Lunt M; Hesselstrand R; Mouthon L; Silman A; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk M; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jordan AC; Jobanputra P; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov N; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman S; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
Ann Rheum Dis; 2017 Jul; 76(7):1207-1218. PubMed ID: 28188239
[TBL] [Abstract][Full Text] [Related]
14. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
Gordon JK; Martyanov V; Franks JM; Bernstein EJ; Szymonifka J; Magro C; Wildman HF; Wood TA; Whitfield ML; Spiera RF
Arthritis Rheumatol; 2018 Feb; 70(2):308-316. PubMed ID: 29073351
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
Denton CP; Merkel PA; Furst DE; Khanna D; Emery P; Hsu VM; Silliman N; Streisand J; Powell J; Akesson A; Coppock J; Hoogen Fv; Herrick A; Mayes MD; Veale D; Haas J; Ledbetter S; Korn JH; Black CM; Seibold JR; ;
Arthritis Rheum; 2007 Jan; 56(1):323-33. PubMed ID: 17195236
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.
Nihtyanova SI; Brough GM; Black CM; Denton CP
Rheumatology (Oxford); 2007 Mar; 46(3):442-5. PubMed ID: 16899504
[TBL] [Abstract][Full Text] [Related]
17. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
18. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial.
Piepers S; Van den Berg-Vos R; Van der Pol WL; Franssen H; Wokke J; Van den Berg L
Brain; 2007 Aug; 130(Pt 8):2004-10. PubMed ID: 17626040
[TBL] [Abstract][Full Text] [Related]
20. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
